Peptide Drug Conjugates (PDCs) have demonstrated significant advancements in target-specific delivery, enhancing therapeutic efficacy and reducing toxicity. However, manufacturing challenges persist, including scale-up processes, yield optimization, cost-efficiency balance, and quality assurance through rigorous analytical methods. 

Our innovative approaches in continuous purification and each manufacturing process achieve high purity and high yield, tailored to your specific needs.

 In our latest white paper, you will find:

• Proposed solutions for purification and analytical challenges in PDC manufacturing

• Experiences and insights in the synthesis of unique peptides, oligonucleotides, and conjugates

Discover how our CDMO services can accelerate the development of your peptides, oligos, and conjugates.
To download the full paper, please enter your information below.